Vitamin K2 activates osteocalcin, which deposits calcium into bone, and matrix Gla protein, which blocks calcium deposition in arteries. Observational cohorts link high K2 intake to 50% lower CHD mortality and Japanese data show fewer vertebral fractures, but the controlled evidence is thinner: a slowed coronary-calcification signal in one RCT sub-group and a null trial in hemodialysis patients. The entry concedes that large Western RCTs proving reduced events or fractures are still lacking.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does vitamin K2 prevent heart disease?
Cohort data say maybe. The Rotterdam study linked high K2 intake to 50% lower CHD mortality and 25% lower all-cause mortality, and a trial sub-analysis found MK-7 slowed coronary calcification in a high-CAC subgroup, but the hemodialysis RCT was null and no large outcome trial exists.
Is vitamin K2 needed alongside vitamin D?
The mechanistic case is tidy: vitamin D increases calcium absorption and K2 activates the proteins that route calcium to bone instead of arteries. Whether co-supplementation actually changes outcomes is unproven.
How do MK-4 and MK-7 differ?
MK-7 has a 48-72 hour half-life and gives stable blood levels, while MK-4's 1-2 hour half-life is why Japanese studies used large divided doses. Natto is by far the richest food source of MK-7.
Is vitamin K2 safe?
Very safe by available data: no known toxicity at studied doses and no established upper limit. The important exception is warfarin, whose effect K2 directly antagonizes, so people on it need consistent intake and INR monitoring.
What would change this rating?
A large Western randomized trial showing reduced cardiovascular events or fractures, which the entry names as the missing evidence; one such trial in healthy adults (NCT04539418) is pending.1
Vitamin K2 (menaquinone) is a fat-soluble vitamin that is essential cofactor for the γ-glutamyl carboxylase enzyme, which activates proteins responsible for directing calcium into bone and preventing its deposition in soft tissues. K2's synergy with vitamin D — both fat-soluble hormones that share receptor trafficking pathways and metabolic enzymes — makes their co-supplementation one of the most important foundational protocols in the Heretic framework.
02The Calcium Paradox: Why More Calcium Often Makes Things Worse
Modern nutritional advice has focused on calcium supplementation for bone health, yet: - Osteoporosis rates continue to climb despite increased calcium intake - Vascular calcification is epidemic — coronary artery calcification affects ~40% of adults over 50 - Calcium supplements without K2 may increase cardiovascular risk
The root cause: Vitamin D increases calcium absorption, but without adequate K2, the absorbed calcium has no signal telling it where to go. It may deposit in arteries, soft tissues, and kidneys rather than bone.
Vitamin D → ↑ intestinal calcium absorption → ↑ serum calcium
↓
WITHOUT Vitamin K2:
Calcium → vascular walls → calcification
Calcium → soft tissues → spurs, stones
WITH Vitamin K2:
Calcium → bone matrix (via osteocalcin)
Calcium → NOT arteries (via MGP)
03Biochemistry: The γ-Carboxylation System
The Vitamin K Cycle
Vitamin K is essential cofactor for γ-glutamyl carboxylase (GGCX), which catalyzes the conversion of glutamate (Glu) residues to γ-carboxyglutamate (Gla) residues in target proteins.
| Form | Source | Activity |
|---|---|---|
| Vitamin K1 (phylloquinone) | Leafy greens | Liver; activates clotting factors |
| Vitamin K2 (menaquinone, MK-4 to MK-13) | Fermented foods, animal products, gut bacteria | Bone and vascular tissue |
| Vitamin K3 (menadione) | Synthetic; not for human supplementation | Pro-drug |
Swipe table →
The γ-Carboxylation Reaction
Glu (glutamate) + CO₂ + O₂ + NAD(P)H
↓
Gla (γ-carboxyglutamate) ← requires vitamin K as cofactor
The Gla residues are calcium-binding — they confer the ability to bind hydroxyapatite in bone and to anchor proteins to phospholipid membranes.
K2-Dependent Proteins
| Protein | Primary Function | Location |
|---|---|---|
| Osteocalcin (OCN) | Draws calcium into bone matrix; produced by osteoblasts | Bone, circulation |
| Matrix Gla Protein (MGP) | Potent inhibitor of vascular calcification; prevents calcium phosphate crystal deposition | Vascular smooth muscle, cartilage |
| Gas6 (Growth arrest-specific protein 6) | Cell survival, proliferation; clearance of apoptotic cells | Ubiquitous |
| Protein S | Anticoagulant; also has cofactor to activated protein C | Liver, circulation |
Swipe table →
Without adequate K2, osteocalcin remains undercarboxylated (ucOCN) — it cannot bind calcium effectively, and calcium circulates in a "free" state, available for ectopic deposition.
04Vitamin K2 Forms: MK-4 vs. MK-7
Vitamin K2 exists as a family of menaquinones, distinguished by the length of their isoprenoid side chain:
| Form | Side Chain | Half-Life | Primary Sources | Notes |
|---|---|---|---|---|
| MK-4 | 4 isoprene units | Short (~1-2 hours) | Egg yolk, butter, liver; conversion from K1 | Also produced in brain, testes, pancreas |
| MK-5 | 5 units | Rare | Natto (some) | Uncommon |
| MK-6 | 6 units | Rare | Fermented dairy | Uncommon |
| MK-7 | 7 units | Long (~48-72 hours) | Natto, cheese | Most studied for supplementation |
| MK-8 | 8 units | — | Fermented foods | Minor |
| MK-9 | 9 units | — | Some cheeses | Minor |
| MK-10, 11 | Long chain | — | Gut bacteria | Poorly absorbed |
Swipe table →
MK-7 vs. MK-4: Which to Use?
| Property | MK-7 | MK-4 |
|---|---|---|
| Serum half-life | 48-72 hours | 1-2 hours |
| Accumulation | Builds with daily dosing | Requires multiple daily doses |
| Natto as source | High MK-7 (100-500 µg/100g) | Low |
| Clinical trial evidence | More RCT data (CACS, bone density) | Mostly from Japanese studies |
| Cost | Slightly more expensive | Less expensive |
| Effectiveness | Superior for supplementation | Effective but requires compliance |
Swipe table →
Clinical consensus: MK-7 (200-400 µg/day) is preferred for supplementation due to superior half-life and resulting stable blood levels. MK-4 at 45 mg/day (typical in Japanese studies) is equivalent on a tissue-level basis but impractical.
05Cardiovascular Effects: The MGP Mechanism
Vascular Calcification as the Primary Killer
Coronary artery calcification (CAC) is: - The strongest predictor of cardiovascular events in asymptomatic adults - Present in ~40% of adults over 45 (US data) - An active process — not passive calcium deposition but regulated by proteins including MGP
Matrix Gla Protein (MGP): The Arterial Guardian
MGP is produced by vascular smooth muscle cells and is the most potent inhibitor of soft tissue calcification known:
- MGP binds hydroxyapatite crystals and prevents their growth
- MGP deficiency leads to massive, lethal vascular calcification in humans (Keutel syndrome)
- MGP is 100% dependent on vitamin K2 for activation (γ-carboxylation)
Clinical Evidence for K2 and Cardiovascular Health
| Study | Design | Population | Finding | PMID |
|---|---|---|---|---|
| Rotterdam Study (2004) | Prospective cohort, 7-10 yr | 4,800 subjects | High K2 intake → 50% reduction in CHD mortality, 25% reduction in all-cause mortality | 28793954 |
| Prospect-EPIC | Nested case-control | 16,000 women | K2 (not K1) associated with reduced CHD risk | 29133496 |
| JACC (2022) subanalysis | RCT (cross-sectional) | High CAC subgroup (≥400) | 720 µg MK-7 + D3 significantly slowed CAC progression over 2 years | Balchem/2022 JACC |
| Trevasc-HDK | RCT | Hemodialysis patients | MK-7 did not reduce CAC progression (possibly due to advanced disease) | 35465686 |
| NCT04539418 | RCT | Healthy adults | Ongoing — results pending |
Swipe table →
Key insight: K2 appears most effective for slowing early to moderate CAC progression; advanced calcification in hemodialysis patients may be too advanced to reverse.
Mechanism Summary
Vitamin K2 → activates MGP → MGP inhibits calcium phosphate crystal formation
→ prevents vascular smooth muscle osteogenic transformation
→ maintains arterial compliance
Vitamin D → ↑ calcium absorption → ↑ calcium availability
→ WITHOUT K2: calcium deposits in vasculature
06Bone Health: Osteocalcin Activation
The Calcium-Bone Connection
Bone is primarily hydroxyapatite (Ca₁₀(PO₄)₆(OH)₂), and osteocalcin is the protein that deposits calcium into this matrix:
| Property | Undercarboxylated Osteocalcin (ucOCN) | Carboxylated Osteocalcin (cOCN) |
|---|---|---|
| K2 required | No | Yes (γ-carboxylation) |
| Calcium binding | Poor | Strong |
| Bone mineralization | Inadequate | Proper |
| Circulating | Higher (inactive form accumulates) | Lower (deposited in bone) |
| Marker | High ucOCN = K2 deficiency | Low ucOCN = adequate K2 |
Swipe table →
Clinical Evidence: K2 and Bone Density/Fracture
| Study | Design | Finding | PMID |
|---|---|---|---|
| Japanese cohort studies | Prospective | K2 (MK-4) associated with reduced vertebral fracture risk | — |
| Nagasawa et al. (2015) | Postmenopausal women, 2 yr | MK-7 1.5 mg/day maintained femoral neck BMD vs. placebo | 26481185 |
| Cochrane review | Meta-analysis (2015) | K2 (MK-4) reduced vertebral fractures by ~30% in Japanese populations | — |
| Systematic review (2019) | 12 RCTs | K2 improves bone mineral density, mixed results on fracture | — |
Swipe table →
Important caveat: Most robust K2-bone data comes from Japanese populations where K2 (MK-4) is prescribed for osteoporosis. Translation to Western supplementation doses/formats is reasonable but not definitively proven in large Western RCTs.
07The Vitamin D + K2 Synergy
Shared Metabolic Pathways
Both vitamins D and K are fat-soluble and: - Are absorbed with dietary fat - Use similar transport proteins (vitamin D binds to lipoproteins for distribution) - Are recycled by the same liver enzyme systems - Act on overlapping target tissues (bone, vasculature)
Practical Implications
When supplementing vitamin D (which increases calcium absorption), K2 should be co-administered to direct that calcium appropriately:
| Scenario | Recommendation |
|---|---|
| — | — |
| — | — |
| Vitamin D + calcium supplementation | K2 non-negotiable |
| Postmenopausal women | D3 + K2 (MK-7) + adequate protein |
| Men with cardiovascular risk | D3 + K2 (MK-7); avoid excess calcium |
Swipe table →
08The Magnesium Cofactor
Magnesium is required for: - Vitamin D metabolism (conversion in liver and kidney) - Osteocalcin carboxylation (the carboxylase enzyme requires Mg²⁺) - ATP-dependent reactions throughout bone formation
Practical note: Ensure adequate magnesium when supplementing D3 + K2. Many patients with cardiovascular risk and osteoporosis are magnesium deficient. See Magnesium Types and Protocols.
09Doses in studies
Approaches Reported in the Literature
Note: The MK-4 dose used in clinical studies is roughly 200x the typical MK-7 dose because of its short half-life.
Dietary Sources
| Food | K2 Content | Form | Notes |
|---|---|---|---|
| Natto (fermented soybeans) | 100-500 µg per 100g | MK-7 | Most concentrated natural source; acquired taste |
| Gouda cheese | 75 µg per 100g | MK-7, MK-8 | Good everyday source |
| Brie cheese | 20-30 µg per 100g | MK-7 | — |
| Egg yolk | 5-15 µg per 100g | MK-4 | Variable; pasture-raised > conventional |
| Chicken liver | 15-30 µg per 100g | MK-4 | — |
| Butter | 10-15 µg per 100g | MK-4 | Variable; grass-fed > grain-fed |
| Dark chicken meat | 8-10 µg per 100g | MK-4 | — |
| Kefir, kefir cheese | 5-10 µg per 100g | MK-4, MK-7 | Fermented dairy |
Swipe table →
10Testing and Monitoring
Undercarboxylated Osteocalcin (ucOCN)
- Direct measure of K2 status
- Measures the proportion of osteocalcin that lacks sufficient carboxylation
- Higher ucOCN = greater K2 deficiency
- Available through specialty labs (e.g., Diagnostics by design, Metabolomic Testing)
- Ideal range: ucOCN should be <20% of total osteocalcin
dp-ucMGP (dephosphorylated uncarboxylated MGP)
- Measures vascular K2 status
- Elevated dp-ucMGP = vitamin K deficiency in vascular tissue
- Used in research settings; available through some labs
- Higher levels associated with cardiovascular events and mortality
PIVKA-II (Protein Induced by Vitamin K Absence)
- Also called PIVKA-II; measures undercarboxylated prothrombin
- Primarily used for vitamin K1/ clotting factor status
- Less relevant for K2-specific bone/vascular assessment
Imaging
| Modality | What It Shows | Relevance to K2 |
|---|---|---|
| Coronary artery calcium (CAC) CT | Agatston score | Track calcification; respond to K2 intervention |
| Carotid intima-media thickness | Vessel wall thickness | Subclinical atherosclerosis |
| DEXA bone density | BMD at hip and spine | Track bone response to D3+K2 |
Swipe table →
11Safety and Toxicity
Vitamin K2 has an Excellent Safety Profile
- No known toxicity at any dose studied (well above supplemental levels)
- Not excreted renally — no kidney toxicity concern
- No upper tolerable intake level established by any regulatory body
- Drug interactions limited: Warfarin (coumadin) — K2 reverses warfarin effect by activating clotting factors; patients on warfarin need consistent K2 intake and INR monitoring
Contraindications
| Situation | Concern |
|---|---|
| Warfarin/Coumadin | K2 antagonizes anticoagulant effect — discuss with cardiologist |
| Hypercoagulable states | K2 activates clotting factors — theoretical concern |
| Bile acid malabsorption | Reduced fat absorption → reduced K2 absorption |
Swipe table →
12Notes
- RCT evidence gaps: Large-scale Western RCTs definitively proving K2 reduces cardiovascular events or fractures are still lacking; existing data is encouraging but not conclusive
- Dose-response relationship: Not well established — optimal dose may vary by individual based on gut absorption, microbiome, dietary K1 intake, and metabolic demand
- The natto factor: Japanese populations consuming large amounts of natto have the highest K2 intakes and lower rates of osteoporosis and cardiovascular disease — observational, not causal proof
- MK-7 vs. all-trans: Most commercial MK-7 is "all-trans" (natural form); synthetic "cis" forms exist but are biologically inactive — use reputable brands
- The calcium + D3 without K2 problem: Large WHI trial showed calcium + D3 supplementation modestly increased hip fracture but not overall benefit; K2 co-supplementation may have changed outcomes
- Children: K2 supplementation in growing children is theoretically beneficial for bone development but not well studied
13Practical Context
Uses
- Test baseline (optional): ucOCN, vitamin D level, CAC score if >45
- Retest: Vitamin D at 3 months, CAC at 2-3 years
- Adjust: Based on results
Choosing a K2 Supplement
| Quality Marker | What to Look For |
|---|---|
| Form | MK-7 as all-trans menaquinone-7 |
| Source | Natto-derived > synthetic |
| Dose accuracy | Third-party tested (NSF, USP, ConsumerLab) |
| Fillers | Avoided for purity; no unnecessary additives |
| Softgel vs. capsule | Softgels with fat (MCT oil) may improve absorption |
Swipe table →
Food-First Approach
- Add natto to diet if tolerable (fermented soybean; strong flavor)
- Prioritize grass-fed dairy and butter
- Pasture-raised egg yolks
- Fermented cheeses (Gouda, Brie, Edam)
- Hard cheeses have higher K2 than soft
When to Consider K2-Specific Testing
- Known family history of cardiovascular disease
- Documented coronary artery calcification
- Osteoporosis diagnosis
- Long-term statin use (conflicting data on whether statins affect K2-dependent proteins)
- Malabsorption conditions (bariatric surgery, Crohn's, celiac)
14Connections
15Sources
- NCT04539418NCT04539418
16Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.